CytRx Corporation (NASDAQ:CYTR) is one of the leading biopharmaceutical development and research company with additional expertise in oncology. As per the reports, the company has updated about a couple of different 1b aldoxorubicin combination studies, which are still in phase one. Both of these studies focus on connecting aldoxorubic with ifosfamide or gemcitabine.
Insights of The Studies:
Both of these entirely focus on combining the standard doses of ifosfamide or gemcitabine with escalating doses of aldoxorubicin. The industry experts consider it an effective initiative. Reports claim that both the combinations are effectively tolerated and productive. Even the lowest level of aldoxorubicin is capable of showing impressive response in different patients with bone cancer and various other soft tissue sarcomas.
The senior management is delighted to make these announcements. According to Dr. Sant Chawla, Director & Principal Investigator, Sarcoma Oncology Center, the early success has boosted the confidence level of everyone. The activity and tolerability of both the combinations have given a lot of reasons to the entire management to feel happy and accomplished. The first patient suffering from osteosarcoma was given treatment with ifosfamide and aldoxorubicin. This patient received PET-demonstrated complete tumor response within the six months time, that too after just five cycles of the combination.
Many other patients have also administered the gemcitabine and aldoxorubic in a combination that showed the shrinkage of the tumor after just two cycles of the treatment. When the combination was tried for the patient who had advanced bone cancer, a deadly and rare cancer, he stopped most of the pain medications. His condition improved so quickly that he stopped taking everything else apart from Advil and started going office once again. These results create a huge base for the future studies and clinical trials.
The management of CytRx Corporation (NASDAQ:CYTR) hopes that the situation will improve in the near future.